Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001867033-25-000003
Filing Date
2025-10-02
Accepted
2025-10-02 17:05:10
Documents
1
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 form4-10022025_051007.html 4  
1 form4-10022025_051007.xml 4 3393
  Complete submission text file 0001867033-25-000003.txt   5130
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Issuer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O VYNE THERAPEUTICS 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address
Zeronda Tyler (Reporting) CIK: 0001867033 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38356 | Film No.: 251370500